Clinical Trials

1,946 enrolled

Breast Neoplasms

NCT00310180 2026-04-13

TAILORx

10,273 enrolled 14 charts

Breast Neoplasms

NCT01272037 2026-04-13

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

5,018 enrolled 14 charts

Carcinoma, Intraductal, Noninfiltrating

NCT04553133 2026-04-13

PF-07104091 as a Single Agent and in Combination Therapy

BreastGynecologicThoracic

157 enrolled

Breast Neoplasms, Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT04895761 2026-04-13

Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer

6 enrolled

Breast Neoplasms

NCT04569747 2026-04-02

ADEPT

393 enrolled

Phase 4 Active not recruiting

Breast Neoplasms

NCT05161195 2026-04-02

Roll-over Study to Allow Continued Access to Ribociclib

134 enrolled

Breast Neoplasms

NCT05514054 2026-04-02

EMBER-4

8,000 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT01872260 2026-04-01

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

255 enrolled

Breast Neoplasms

NCT05307705 2026-03-27

PIKASSO-01

193 enrolled

Breast Neoplasms

NCT04095364 2026-03-24

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

450 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04293393 2026-03-12

CARABELA

200 enrolled 27 charts

Breast Neoplasms

NCT02712723 2026-03-11

FELINE

121 enrolled 9 charts

Breast Neoplasms

NCT03006172 2026-03-11

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

200 enrolled

Breast Neoplasms

NCT04931342 2026-03-10

BOUQUET

176 enrolled

Ovarian Neoplasms

NCT04393285 2026-03-09

Abemaciclib and Letrozole to Treat Endometrial Cancer

53 enrolled

Phase NA Active not recruiting

Endometrial Neoplasms

NCT07448272 2026-03-04

PCOS OID

80 enrolled

Polycystic Ovary Syndrome

NCT02778685 2026-02-24

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

47 enrolled 17 charts

Breast Neoplasms

NCT03179904 2026-02-24

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

17 enrolled 10 charts

Advanced Breast Carcinoma

NCT04546009 2026-02-20

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

992 enrolled

Breast Neoplasms

NCT02947685 2026-02-12

PATINA

518 enrolled 15 charts

Breast Neoplasms

NCT03008408 2026-02-11

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

90 enrolled

Endometrial Neoplasms

NCT01674140 2026-02-10

e3

1,939 enrolled 15 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT05909397 2026-02-10

VERITAC-3

59 enrolled

Breast Neoplasms

NCT02763566 2026-02-05

MONARCH plus

463 enrolled 20 charts

Breast Neoplasms

NCT02246621 2026-02-03

MONARCH 3

493 enrolled 23 charts 1 FDA

Breast Neoplasms

NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

198 enrolled

Breast Neoplasms

NCT03879577 2026-01-21

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

53 enrolled 13 charts

Breast Neoplasms

NCT04568616 2026-01-20

NAOMI

178 enrolled

Breast Neoplasms

NCT04964934 2026-01-16

SERENA-6

315 enrolled

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site

NCT06001762 2026-01-16

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

90 enrolled

Breast Neoplasms

NCT04584853 2026-01-14

POETIC-A

123 enrolled

Breast Cancer Female

NCT04906395 2026-01-13

OVELIA

250 enrolled

Breast Neoplasms, Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT05150652 2026-01-07

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

8 enrolled

Breast Neoplasms

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

GastrointestinalGenitourinaryGynecologic

30 enrolled

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT03673124 2025-12-23

Ribociclib and Letrozole Treatment in Ovarian Cancer

51 enrolled 19 charts

Cystadenocarcinoma, Serous

NCT05226871 2025-11-25

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

35 enrolled

BreastHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms

NCT01068249 2025-11-18

Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

42 enrolled 11 charts

Recurrence, Endometrial Neoplasms

NCT01797523 2025-11-06

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma

62 enrolled

Endometrial Neoplasms

NCT04272801 2025-10-22

POWER

84 enrolled 9 charts

Breast Neoplasms

NCT04557449 2025-10-01

CDK4i

BreastGastrointestinalGenitourinarySarcomaThoracic

362 enrolled

Adenocarcinoma of Lung, Breast Neoplasms, Liposarcoma, Prostatic Neoplasms, Colorectal Neoplasms

NCT03959891 2025-09-29

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

77 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT02562118 2025-09-25

Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer

40 enrolled

Breast Neoplasms

NCT04158362 2025-09-22

AMBRE

180 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT03283384 2025-09-19

NEOLBC

100 enrolled

Breast Neoplasms

NCT03425838 2025-09-19

Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

1,050 enrolled

Breast Neoplasm Female

NCT05257395 2025-07-17

A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer

397 enrolled

Breast Neoplasms

NCT06570031 2025-07-02

ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

46 enrolled

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT06253195 2025-06-05

BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

33 enrolled